SHZ:002020
Zhejiang Jingxin Pharmaceutical Co., Ltd. · SHZ · Healthcare · CNY · FY for 2025
Figures on this page computed 2026-11-08 13:25 UTC
Last close
n/aCNY
Market data
13.4xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- computed
- Computed from the filing for 2025
13.4%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
18.6%Net margin
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
14.2%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
0.05Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
2.8%Dividend yield
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- computed
Growth is the furthest below its sector's middle: 0.37 against 0.47 on the market's range.
Follow one yuan
lens 1 of 9After what it costs to make
50.1%
After running the business
20.8%
After interest and tax
18.6%
After what it must reinvest
14.2%
Kept after the dividend
7.2%
The five stops
5 of 5 read- After what it costs to make2,040,730,38750.1%
- After running the business844,785,50820.8%
- After interest and tax757,979,43918.6%
- After what it must reinvest578,496,25014.2%
- Kept after the dividend293,642,5057.2%
Of every unit of sales, 0.07 is still there after the dividend.
Of every unit of sales, 0.07 is still there after the dividend.
Every figure in this lens
Except where said otherwise: Computed from the filing for 2025
Sales4,069,361,419
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
After what it costs to make2,040,730,387
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
After running the business844,785,508
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
After interest and tax757,979,439
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
After what it must reinvest578,496,250
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
Kept after the dividend293,642,505
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY